Summit Therapeutics (SMMT)
(Real Time Quote from BATS)
$12.66 USD
-0.20 (-1.56%)
Updated Aug 30, 2024 12:10 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Summit Therapeutics PLC (SMMT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.33 | $16.00 | $13.00 | 11.43% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Summit Therapeutics PLC comes to $14.33. The forecasts range from a low of $13.00 to a high of $16.00. The average price target represents an increase of 11.43% from the last closing price of $12.86.
Analyst Price Targets (3 )
Broker Rating
Summit Therapeutics PLC currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on two recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SMMT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 2 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/12/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Not Available | Strong Buy |
7/17/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 3 |
Average Target Price | $14.33 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | -0.07 |